BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

A research team at the University of Vienna, led by medicinal chemist Markus Muttenthaler, has developed a new class of oral ...

And two weeks ago, the FDA officially proposed removing it as an active ingredient in oral over-the-counter drugs for nasal ...

A research team has developed a new class of oral peptide therapeutic leads for treating chronic abdominal pain. This groundbreaking innovation offers a safe, non-opioid-based solution for conditions ...

The global over-the-counter (OTC) pain medication market is poised for steady growth, with its market size expected to attain ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin that drives childbirth contractions.

In 2023, the then 49-year-old went to her physician with painful headaches, blurring vision, pain and swelling of her eyes ...

A mother says years of painful headaches and speech issues from brain tumors were caused by prolonged use of a Pfizer birth ...

U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...

“I worry about patients who are dependent on future innovation who are in the Medicare population,” said Scott Gottlieb, a former Food and Drug Administration commissioner who’s now a partner at New ...